Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2019 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
May 09, 2019 08:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

Continued enrollment of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerNet proceeds of approximately $71 million from completion...
April 18, 2019 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers

HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development...
March 13, 2019 16:07 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Upcoming William Blair Cancer Immunotherapy Conference

SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...
March 07, 2019 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...
February 20, 2019 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Present at SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...